School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Network of Dermatology Research (NDR), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Dermatol Ther. 2021 Nov;34(6):e15113. doi: 10.1111/dth.15113. Epub 2021 Sep 7.
Since the emergence of the new coronavirus disease 19 (COVID-19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare-ups of underlying dermatologic disease in patients with COVID-19. A total of 17 articles were recovered reporting on flare-ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus erythematosus, acrodermatitis continua of Hallopeau, systemic sclerosis sine scleroderma, and Sézary syndrome (SS). Out of these, psoriasis and alopecia areata were the most common conditions. However, most cases of psoriasis could have been attributed to either antimalarial agents that were initially used for the treatment of COVID-19 or discontinuation of treatment following SARS-CoV2 infection.
自新型冠状病毒病 19 （COVID-19 ）大流行以来，人们一直担心患有慢性自身免疫性疾病的患者，包括皮肤病，这些患者在感染严重急性呼吸综合征冠状病毒 2 （SARS-CoV2 ）后，这些潜在疾病是否会恶化。我们进行了一项系统评价，以评估 COVID-19 患者潜在皮肤病发作的表现、感染后表现变化、诊断和治疗。共检索到 17 篇关于皮肤病发作的文章，包括寻常型天疱疮、银屑病、亚急性皮肤型狼疮、Hallopeau 连续性肢端皮炎、无硬皮病的系统性硬化症和 Sézary 综合征。其中，银屑病和斑秃是最常见的疾病。然而，大多数银屑病病例可能归因于最初用于治疗 COVID-19 的抗疟药物或 SARS-CoV2 感染后停止治疗。
